Determinants of Nucleotide-Binding Selectivity of Malic Enzyme by Hsieh, Ju-Yi et al.
Determinants of Nucleotide-Binding Selectivity of Malic
Enzyme
Ju-Yi Hsieh
1., Meng-Chun Chen
1., Hui-Chih Hung
1,2,3*
1Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan, 2Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung,
Taiwan, 3Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan
Abstract
Malic enzymes have high cofactor selectivity. An isoform-specific distribution of residues 314, 346, 347 and 362 implies that
they may play key roles in determining the cofactor specificity. Currently, Glu314, Ser346, Lys347 and Lys362 in human c-
NADP-ME were changed to the corresponding residues of human m-NAD(P)-ME (Glu, Lys, Tyr and Gln, respectively) or
Ascaris suum m-NAD-ME (Ala, Ile, Asp and His, respectively). Kinetic data demonstrated that the S346K/K347Y/K362Q c-
NADP-ME was transformed into a debilitated NAD
+-utilizing enzyme, as shown by a severe decrease in catalytic efficiency
using NADP
+ as the cofactor without a significant increase in catalysis using NAD
+ as the cofactor. However, the S346K/
K347Y/K362H enzyme displayed an enhanced value for kcat,NAD, suggesting that His at residue 362 may be more beneficial
than Gln for NAD
+ binding. Furthermore, the S346I/K347D/K362H mutant had a very large Km,NADP value compared to other
mutants, suggesting that this mutant exclusively utilizes NAD
+ as its cofactor. Since the S346K/K347Y/K362Q, S346K/K347Y/
K362H and S346I/K347D/K362H c-NADP-ME mutants did not show significant reductions in their Km,NAD values, the E314A
mutation was then introduced into these triple mutants. Comparison of the kinetic parameters of each triple-quadruple
mutant pair (for example, S346K/K347Y/K362Q versus E314A/S346K/K347Y/K362Q) revealed that all of the Km values for
NAD
+ and NADP
+ of the quadruple mutants were significantly decreased, while either kcat,NAD or kcat,NADP was substantially
increased. By adding the E314A mutation to these triple mutant enzymes, the E314A/S346K/K347Y/K362Q, E314A/S346K/
K347Y/K362H and E314A/S346I/K347D/K362H c-NADP-ME variants are no longer debilitated but become mainly NAD
+-
utilizing enzymes by a considerable increase in catalysis using NAD
+ as the cofactor. These results suggest that abolishing
the repulsive effect of Glu314 in these quadruple mutants increases the binding affinity of NAD
+. Here, we demonstrate that
a series of E314A-containing c-NADP-ME quadruple mutants have been changed to NAD
+-utilizing enzymes by abrogating
NADP
+ binding and increasing NAD
+ binding.
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Introduction
Malic enzyme catalyzes a reversible oxidative decarboxyla-
tion that converts L-malate into CO2 and pyruvate with the
simultaneous reduction of NAD(P)
+ to NAD(P)H [1–3] and
requires a divalent metal ion (Mn
2+ or Mg
2+) for catalysis. The
enzyme is widely distributed in nature, with conserved sequences
and similar tertiary structural topologies among different species
[4–7]. Mammalian malic enzymes are classified into three isoforms
according to their cofactor specificities and subcellular localiza-
tions: cytosolic NADP
+-dependent (c-NADP-ME) [8,9], mito-
chondrial NADP
+-dependent (m-NADP-ME) [10], and mitochon-
drial NAD(P)
+-dependent malic enzymes (m-NAD(P)-ME) [11–
13]. The m-NAD(P)-ME isoform can use either NAD
+ or NADP
+
as a cofactor, but the enzyme favors NAD
+ as the physiological
cofactor [11,14]. Furthermore, this enzyme isoform is an allosteric
enzyme [15,16] that can be inhibited by ATP [17,18]. Malic
enzyme has a specific role in cells. Both c-NADP-ME and m-
NADP-ME act as NADPH suppliers during the biosynthesis of
long-chain fatty acids and steroids, so they are defined as lipogenic
enzymes [1,19,20]. Human m-NAD(P)-ME is believed to play an
important role in the metabolism of glutamine in fast-growing
tissues and tumors [21–23]. Therefore, m-NAD(P)-ME is regarded
as a potential target for cancer therapy.
The crystal structures of malic enzyme in complex with its
substrate, cofactor, inhibitor and regulator have been solved
[5,6,24–28]. Structural data reveal malic enzyme to be a
homotetramer with a dimer-of-dimers quaternary structure
(Figure 1A); each monomer contains an active site. The dimer
interface formed by subunits A and B (or by C and D) displays
more intimate contact than the tetramer interface formed by
subunits A and D (or by B and C). Structural data regarding the
binary complexes (NAD
+) [7], ternary complexes (NAD
+ and
Lu
3+) [26], quaternary complexes (NAD
+, substrate analog
inhibitors and divalent cation) [24] and pentary complexes
(NAD
+/NADH, substrate malate/pyruvate, divalent cation, and
allosteric activator fumarate) [27,28] of human m-NAD(P)-ME
reveal that the enzyme may exist either in open forms or closed
forms and that it may undergo an open-closed transition during
catalysis [4,24]. The structure of pigeon c-NADP-ME in
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25312Figure 1. Nucleotide-binding site of c-NADP-ME. (A) Tetramer of pigeon c-NADP-ME (PDB code 1GQ2). The active site with Mn
2+ and NADP
+ in
each subunit is indicated. NADP
+ in the active site is colored yellow, and the Mn
2+ ion is red; they are displayed in the sphere model. (B) Multiple
sequence alignments of three clusters of malic enzyme isoforms around the nucleotide-binding region of the active site. Amino acid sequences of
malic enzymes were searched using BLAST [34], and the alignments were generated by Clustal W [35]. This figure was generated using the BioEdit
sequence alignment editor program [36]. (C) The binding mode of NADP
+ in the active site of c-NADP-ME (PDB code 1GQ2). Ser346, Lys347 and
Lys362 are colored green, purple and pink, respectively, and they are shown in a ball-and-stick model. The yellow dashed lines represent the polar
contacts between amino acid residues and NADP
+. These figures were generated using PyMOL (DeLano Scientific LLC, San Carlos, CA).
doi:10.1371/journal.pone.0025312.g001
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+, oxalate, and a divalent ion is
in a closed form [6]. However, the structure of the open form for
the cytosolic isoform has not yet been determined. Furthermore, c-
NADP-ME is not a cooperative or allosteric enzyme, and it is less
inhibited by ATP [29]. Thus, it appears to lack the allosteric and
exo sites that are present in m-NAD(P)-ME.
The nucleotide-binding regions of malic enzyme isoforms are
different. Crystal structures of the quaternary complexes of pigeon
c-NADP-ME reveal that the 29-phosphate group of NADP
+
interacts with Ser346 and the ammonium group of Lys362 [6].
Previous studies on pigeon c-NADP-ME suggest that NADP
+
specificity is determined by an electrostatic interaction between the
e-amino group of Lys362 and the 29-phosphate of NADP
+ [30].
Moreover, kinetic studies on human m-NAD(P)-ME demonstrate
that the K346S/Y347K/Q362K substitutions in human m-
NAD(P)-ME cause it to be a NADP
+-dependent enzyme [14,
31]. Lys346 in human m-NAD(P)-ME has minor effects on
cofactor preference but has a significant impact on isoform-specific
ATP inhibition [29]. Tyr347 is also a determinant of the dual-
cofactor specificity of human m-NAD(P)-ME [31]. Multiple
sequence alignments reveal an isoform-specific distribution of
residues 346, 347 and 362, which are Ser, Lys and Lys,
respectively, in NADP
+-dependent malic enzyme and Ile, Asp
and His, respectively, in NAD
+-dependent malic enzyme
(Figure 1B), implying that they may play key roles in determining
the cofactor specificity of malic enzyme. In addition, our previous
studies showed that Glu314 may be involved in the binding
affinities of NAD
+ and ATP [18]. In the present study, Glu314,
Ser346, Lys347 and Lys362 in human c-NADP-ME were changed
to the corresponding residues of human m-NAD(P)-ME and
Ascaris suum m-NAD-ME. Here, we provide full kinetic evidence to
reveal the determinants that govern the nucleotide-binding
selectivity of malic enzyme.
Results
Kinetic properties of human recombinant c-NADP-ME
Kinetic parameters of c-NADP-ME determined using NADP
+
or NAD
+ as the cofactor (Km,NADP and Km,NAD) are shown in
Table 1. For the wild-type (WT) enzyme, the Km,NADP and Km,NAD
values of human c-NADP-ME were 0.0035 mM and 18.57 mM,
respectively, revealing that the enzyme had a much higher
apparent affinity for NADP
+ than NAD
+. Furthermore, the
kcat,NADP value (126 s
21) of the human c-NADP-ME was higher
than the kcat,NAD value (51 s
21). The kcat,NADP/Km,NADP and
kcat,NAD/Km,NAD values of the enzyme were 3.6610
7 and
2.8610
3 M
21s
21, respectively, a 10
4-fold difference.
Most of the human mutant c-NADP-ME variants listed in
Table 1 showed notably increased Km,NADP values but exhibited
relatively minor changes in Km,NAD values. The K362Q enzyme
displayed a significant (over 140-fold) elevation in Km,NADP value
compared with that of WT c-NADP-ME but no significant
changes in the kcat,NADP value, again showing that Lys362 is the
key residue contributing to binding the 29-phosphate of NADP
+.
In Ascaris suum m-NAD-ME, residue 362 is His (Figure 1B). The
K362H enzyme also displayed a considerable elevation in
Km,NADP, but the kcat,NAD value was elevated compared to the
WT and K362Q c-NADP-ME, indicating that His362 may be
advantageous for NAD
+-specific catalysis in NAD-ME. The
S346K and K347Y enzyme variants showed a 3- to 5-fold
increase in Km,NADP compared to the WT enzyme, and the
Km,NADP value of the double mutant S346K/K347Y further
increased 30-fold. Furthermore, the Km,NADP values of the double
mutants S346K/K362Q and K347Y/K362Q were much higher
than that of the single mutant K362Q and more than several
thousand times higher than that of WT c-NADP-ME. These
results suggest that both Ser346 and Lys347 represent additional
factors that determine the NADP
+ specificity of human c-NADP-
ME. Indeed, both double-mutant enzymes, S346K/K362Q and
K347Y/K362Q, displayed dual-cofactor specificity, as both of
them exhibited similar values for Km,NADP and Km,NAD and for
kcat,NADP and kcat,NAD. For S346K/K347Y/K362Q, the Km,NADP
value was elevated to 16.9 mM, which was approximately 3,400
times greater than that of the WT c-NADP-ME. At the same time,
the kcat,NADP of this triple mutant was reduced to only 10% of WT,
and the Km,NAD value decreased about twofold, with a twofold
increase in kcat,NAD, indicating that this mutant was transformed
into an NAD
+-favoring enzyme. The kcat,NADP/Km,NADP and
kcat,NAD/Km,NAD values of this triple-mutant enzyme were 8.8610
2
and 1.2610
4 M
21s
21, respectively.
Comparing the kinetic parameters of S346K/K362Q and
S346K/K347Y/K362Q, the Km,NADP value of the triple mutant
was slightly elevated with a significant decrease in kcat,NADP.
However, the Km,NAD and kcat,NAD values were not significantly
changed by adding the K347Y mutation to the S346K/K362Q
enzyme. In contrast, the major differences in kinetic parameters
between K347Y/K362Q and S346K/K347Y/K362Q were that
the kcat,NADP value was further reduced and that the kcat,NAD value
was increased significantly by adding the S346K mutation to the
K347Y/K362Q enzyme. These results indicate that the K347Y
mutation contributed considerably to the decrease in kcat,NADP,
whereas the S346K mutation had a significant effect on the
increase in kcat,NAD with a concurrent decrease in kcat,NADP.
The S346K/K347Y/K362Q c-NADP-ME displayed an elevat-
ed Km,NADP value, but with no concurrent reduction in its Km,NAD
value, revealing that the mutation of Ser346 to Lys, Lys347 to Tyr
and Lys362 to Gln significantly reduced the NADP
+ specificity
without increasing its apparent affinity for NAD
+. However,
mutation of Lys362 to His instead of Gln caused the enzyme to
have a greater kcat,NAD value than the enzyme replaced by Gln at
residue 362 [K362H (108 s
21) vs. K362Q (60 s
21) and S346K/
K347Y/K362H (219 s
21) vs. S346K/K347Y/K362Q (124 s
21)].
These results suggested that residue 362 also determines the
specificity of the cofactor used by malic enzyme. In c-NADP-ME,
which is NADP
+-specific, this residue is a positively charged Lys,
while this residue in m-NAD-ME is His, which is beneficial for
NAD
+ utilization; in the m-NAD(P)-ME, which has dual-cofactor
specificity, this residue is a neutrally charged Gln. Furthermore,
mutation of Ser346 to Ile, Lys347 to Asp and Lys362 to His (S346I/
K347D/K362H), the respective amino acid residues on Ascaris suum
m-NAD-ME, causes the enzyme to have a very large Km,NADP
value. The exclusive use of NAD
+ by the S346I/K347D/K362H
mutant is due to a loss of affinity for NADP
+ as the cofactor rather
than greater affinity for NAD
+. The kcat,NADP/Km,NADP and
kcat,NAD/Km,NAD values of this triple-mutant enzyme were 11.2
and 2.9610
4 M
21s
21, respectively.
Because the S346K/K347Y/K362Q, S346K/K347Y/K362H
and S346I/K347D/K362H c-NADP-ME mutants did not show
reductions in their Km,NAD values, additional factors may be involved
in nucleotide-binding affinity. Our previous studies demonstrated that
Glu314 may have repulsive effects on NAD
+ and ATP in human m-
NAD(P)-ME [18], as the E314A mutant displayed lower Km,NAD and
Ki,ATP values than WT. Glu314 is conserved in most MEs; however,
this residue is Ala in Ascaris suum m-NAD-ME (Figure 1B). Structural
studies of the Ascaris and human ME?NAD binary complexes revealed
that residue 314 may interact with the bisphosphate of the NAD
moiety [5]. To further investigate whether Glu314 is an influential
factor in nucleotide binding, the quadruple mutants E314A/S346K/
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S346I/K347D/K362H of c-NADP-ME were created. Comparison
of the kinetic parameters of each triple-quadruple mutant pair (for
example, S346K/K347Y/K362Q versus E314A/S346K/K347Y/
K362Q) revealed that all of the Km values for NAD
+ and NADP
+ of
the quadruple mutants were significantly decreased, while either
kcat,NAD or kcat,NADP was substantially increased (Table 1). We believed
that the significant change in these kinetic parameters, especially for
the binding of NAD
+, was caused by the mutation of Glu314 to Ala.
The Km,NAD was drastically decreased and the kcat,NAD value was
increased for the E314A single mutant (Table 1). By adding the
E314A mutation to these triple mutant enzymes, their Km,NAD values
were reduced nearly 10-fold (Table 1).
Human m-NAD(P)-ME is a non-cooperative enzyme for substrate
L-malate binding. Table 1 also lists the Km values of L-malate using
NADP
+ or NAD
+ as the cofactor (Km,mal(NADP) and Km,mal(NAD)). The
Km,mal(NADP) and Km,mal(NAD) values of c-NADP-ME were 0.9 mM
and 5.0 mM, respectively. There were no significant differences in
Km,mal(NADP) for WT, E314A, S346K, E314A/S346K, K347Y,
K362Q and S346K/K347Y c-NADP-ME and the value of
Km,mal(NADP) for K362H, S346K/K362Q, K347Y/K362Q,
S346K/K347Y/K362Q, E314A/S346K/K347Y/K362Q, S346K/
K347Y/K362H and E314A/S346K/K347Y/K362H were 3- to 10-
fold larger than that of WT.However, the Km,mal(NADP) value of S346I/
K347D/K362H and E314A/S346I/K347D/K362H were 32 mM
and 21 mM, respectively, over 20-fold larger than that of WT. In
addition, the values of Km,mal(NAD) for WT and mutant c-NADP-ME
did not display significant differences. Considering these kinetic data
together, we can conclude that multiple mutations of E314A, S346K,
K347Y and K362Q have profound effects on the enzyme by
increasing Km,NADP and Km,mal(NADP), significantly decreasing kcat,NADP
and increasing Km,NAD and kcat,NAD; however, these mutations had
only minor influences on Km,mal(NAD).
Inhibitory effect of ATP on c-NADP-ME
The enzyme c-NADP-ME is much less sensitive to ATP
inhibition than m-NAD(P)-ME [31]. Unlike m-NAD(P)-ME,
which is inhibited by ATP with a inhibition constant (Ki) of 0.7–
1.2 mM, c-NADP-ME showed less inhibition by ATP with a Ki
value of 5–17 mM [18,29,31]. We have reported that Glu314 and
Lys346 are influential factors for the ATP sensitivity of human m-
NAD(P)-ME [18,29] and have opposite effects. The E314A
human m-NAD(P)-ME is more sensitive to ATP inhibition with
a smaller Ki,ATP value of 0.5 mM [18]. In contrast, human m-
NAD(P)-ME enzymes containing the K346S mutation are much
less sensitive to ATP inhibition with larger Ki,ATP values [31].
Here, we examined the inhibitory effect of ATP on WT and
mutant c-NADP-ME and determined the inhibition constants of
these enzymes either with NAD
+ or NADP
+ as the cofactor,
Ki,ATP(NAD) and Ki,ATP(NADP). WT c-NADP-ME, with NAD
+ as the
cofactor, showed slight (approximately 10%) inhibition of activity
by ATP (Figure 2A, closed circles). The E314A and E314A/
S346K enzymes displayed approximately 50% and 70%, respec-
tively, inhibition by ATP (Figure 2A, open circles and triangles,
respectively). The quadruple mutants containing both E314A and
S346K (E314A/S346K/K347Y/K362Q and E314A/S346K/
K347Y/K362H) demonstrated mild ATP inhibition (Figure 2A,
open and closed squares, respectively). In contrast, the quadruple
mutant E314A/S346I/K347D/K362H was not inhibited by ATP
(Figure 2A, closed diamonds) despite containing the E314A
substitution. The inhibitory effect of ATP with NADP
+ as the
cofactor was less obvious than when NAD
+ was the cofactor for
these enzymes (Figure 2B).
All of these enzymes presented competitive inhibition patterns
either with NAD
+ or NADP
+ as the cofactor (data not shown). The
ATP inhibition demonstrated a competitive inhibition pattern
with a inhibition constant of ATP with respect to NAD
+
(Ki,ATP(NAD)) for WT c-NADP-ME of 23.261.4 mM (Table 2).
The E314A and E314A/S346K enzymes demonstrated a
competitive inhibition pattern with a much smaller Ki,ATP (NAD)
value of 0.7360.14 mM and 0.73.60.11 mM, respectively
(Table 2). The Ki,ATP(NAD) value of the quadruple mutant,
E314A/S346K/K347Y/K362Q, was 3.360.3 mM (Table 2).
The inhibition constant of ATP with respect to NADP
+ for WT
was 20.663.0 mM, comparable to that with respect to NAD
+
(Table 2). Conversely, the Ki,ATP(NADP) values of E314A and
Figure 2. Inhibitory effect of ATP on human WT and mutant c-NADP-ME. The inhibited enzyme activities were assayed with NAD
+ (A)o r
NADP
+ (B) as the cofactor. The assay mixture contains 40 mM malate, 10 mM MgCl2, and 1 mM NAD
+ or NADP
+. The ATP concentration ranged from
0 to 3 mM.
doi:10.1371/journal.pone.0025312.g002
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tively, similar to that of WT but larger than that with respect to
NAD
+ (Table 2). The Ki,ATP(NADP) value of E314A/S346K/
K347Y/K362Q was 3.960.5 mM, smaller than that of WT and
comparable to that with respect to NAD
+ (Table 2). These
inhibition data demonstrate that although the quadruple mutants
have significantly reduced their NADP
+ preference and shifted
their cofactor preference toward NAD
+, their sensitivity to ATP
inhibition was not significantly elevated, suggesting that cofactor
preference is not associated with inhibition by ATP.
Discussion
Our previous studies on human m-NAD(P)-ME have suggested
that Lys346, Tyr347 and Gln362 together govern the dual-
cofactor specificity of the enzyme. Mutation of these residues to
the respective amino acid residues in c-NADP-ME (Ser346,
Lys347 and Lys362) causes the enzyme to shift its cofactor
preference from NAD
+ to NADP
+ [31]. In addition, Glu314 in
human m-NAD(P)-ME seems to have a repulsive effect on NAD
+
and ATP [18]. Here, we demonstrate that a series of E314A-
containing quadruple-mutant c-NADP-ME variants are changed
to NAD
+-utilizing enzymes by abrogating NADP
+ binding and
increasing the binding of NAD
+.
Kinetic data demonstrated that the S346K/K347Y/K362Q c-
NADP-ME was transformed into a debilitated NAD
+-utilizing
malic enzyme by a severe decrease in catalytic efficiency using
NADP
+ as the cofactor without a significant increase in catalysis
using NAD
+ as the cofactor. However, the S346K/K347Y/
K362H enzyme showed enhanced turnover using NAD
+ as the
cofactor (kcat,NAD, Table 1), suggesting that His at residue 362 may
be more beneficial than Gln in NAD
+ binding. The E314A
mutation was then introduced into these triple mutants. For the
E314A/S346K/K347Y/K362Q c-NADP-ME, its kcat/
Km,NAD(P)*Km,mal is 2.3 s
21mM
22 using NADP
+ as the cofactor,
and 73 s
21mM
22 using NAD
+ as the cofactor (Table 3). The fold
decrease in kcat,NADP/Km,NADP*Km,mal relative to WT is 1.5610
4;
whereas the fold increase in kcat,NAD/Km,NAD*Km,mal is 1.4610
2
(Table 3), indicating that the presence of E314A in the E314A/
S346K/K347Y/K362Q c-NADP-ME transforms the debilitated
triple mutant enzyme into a preferentially NAD
+-utilizing enzyme;
the quadruple mutant displays a considerable increase in catalysis
using NAD
+ as the cofactor. For the E314A/S346K/K347Y/
K362H c-NADP-ME, its kcat/Km,NAD(P)*Km,mal is 1.3 s
21mM
22
when using NADP
+ as the cofactor, and 239 s
21mM
22 when
using NAD
+ as the cofactor (Table 3). The fold decrease in
kcat,NADP/Km,NADP*Km,mal relative to WT is 2.5610
4; whereas the
fold increase in kcat,NAD/Km,NAD*Km,mal is 4.5610
2 (Table 3).
Indeed, this quadruple mutant is the best predominantly NAD
+-
using enzyme in this report, suggesting that elimination of the
repulsive effect of Glu314 in these quadruple mutants increases the
binding affinity of NAD
+ (Table 1).
The S346I/K347D/K362H enzyme displayed very large
Km,NADP and Km,mal(NADP) values with an increased kcat,NAD value
(Table 1). The kcat/Km,NAD(P)*Km,mal of S346I/K347D/K362H c-
NADP-ME is only 3.5610
24 s
21mM
22 when using NADP
+ as
the cofactor; the fold decrease in kcat,NADP/Km,NADP*Km,mal
Table 2. Inhibition constants of ATP for human c-NADP-ME.
c-NADP-ME Ki,ATP(NAD) (mM) Ki,ATP(NADP) (mM)
WT 23.261.4 20.663.0
E314A 0.7360.14 18.162.6
E314A/S346K 0.7360.11 17.462.6
E314A/S346K/K347Y/K362Q 3.360.3 3.960.5
doi:10.1371/journal.pone.0025312.t002
Table 3. Specificity constants for human wild-type and nucleotide-binding mutant c-NADP-ME variants.
c-NADP-ME
kcat,NADP/
Km,NADP*
Km,mal(NADP)
(s
21 mM
22)
Fold
decrease in
kcat,NADP/Km,NADP*
Km,mal(NADP)
kcat,NAD/
Km,NAD*
Km,mal(NAD)
(s
21 mM
22)
Fold increase
in kcat,NAD/
Km,NAD*
Km,mal(NAD)
WT 32809 6 6633 1 0.5 6 0.1 1
E314A 137625 6 39042 0.2 19 6 5.3 35
S346K 12404 6 1843 2.6 0.3 6 0.04 0.5
E314A/S346K 42947 6 5948 0.8 6.2 6 1.0 12
K347Y 2733 6 173 12 0.7 6 0.2 1.3
K362Q 115 6 9.1 2.9610
2 0.9 6 0.2 1.7
K362H 117 6 11.4 2.8610
2 1 6 0.2 1.8
S346K/K347Y 810 6 147 41 0.7 6 0.1 1.3
S346K/K362Q 6 6 0.71 5.8610
3 2.1 6 0.4 3.9
K347Y/K362Q 1.3 6 0.070 2.5610
4 0.3 6 0.04 0.6
S346K/K347Y/K362Q 0.1 6 0.017 3.4610
5 3.4 6 0.4 6.4
E314A/S346K/K347Y/K362Q 2.3 6 0.9 1.5610
4 73 6 15 1.4610
2
S346K/K347Y/K362H 0.03 6 0.011 1.2610
6 5.3 6 0.9 10
E314A/S346K/K347Y/K362H 1.3 6 0.22 2.5610
4 239 6 66 4.5610
2
S346I/K347D/K362H 3.5610
24 6 3.1610
24 9.4610
7 3.7 6 0.5 6.8
E314A/S346I/K347D/K362H 0.02 6 0.010 1.1610
6 59 6 11.8 1.1610
2
doi:10.1371/journal.pone.0025312.t003
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7 (Table 3), indicating a strong rejection
of NADP
+ by this triple mutant. However, the E314A/S346I/
K347D/K362H enzyme displayed less of a bias against NADP
+
(Km,NADP). For this quadruple mutant, the kcat/Km,NAD(P)*Km,mal is
0.02 s
21mM
22 when using NADP
+ as the cofactor, and
59 s
21mM
22 when using NAD
+ as the cofactor (Table 3). The
fold decrease in kcat,NADP/Km,NADP*Km,mal relative to WT is
1.1610
6; whereas the fold increase in kcat,NAD/Km,NAD*Km,mal is
1.1610
2 (Table 3).
Factors involved in ATP inhibition of c-NADP-ME
The E314A and E314A/S346K c-NADP-ME variants are
sensitive to ATP inhibition when using NAD
+ as the cofactor, but
not when using NADP
+ (Figure 2). These two mutant enzymes,
which mainly retain their NADP
+ selectivity, may be protected by
NADP
+. Thus, ATP is a poor competitive inhibitor with respect to
NADP
+ for the NADP
+-specific malic enzyme.
TheE314A/S346K/K347Y/K362Q,E314A/S346K/K347Y/
K362H and E314A/S346K/K347Y/K362H enzymes display
altered cofactor specificity from NADP
+ to NAD
+. These quadruple
mutantswithE314AorE314A/S346Kmutations,however,areless
sensitive to ATP inhibition than the E314A and E314A/S346K c-
NADP-ME regardless of whether NADP
+ or NAD
+ is used as the
cofactor (Figure 2, Table 2). Table 4 summarizes the amino acid
identities at residues 314, 346, 347 and 362 for these c-NADP-MEs.
The E314A and E314A/S346K c-NADP-ME variants may have a
more positively charged nucleotide-binding site with greater affinity
for ATP and thus greater sensitivity to ATP inhibition. The
quadruple mutants, however, with a less positively charged
nucleotide-binding site, may not possess a great enough affinity
for ATP.
The S346K and E314A c-NADP-ME may have similar
positively charged nucleotide-binding sites because the net charges
of the sites are apparently equivalent. However, the S346K c-
NADP-ME is less sensitive to ATP inhibition than E314A c-
NADP-ME. Furthermore, the E314A m-NAD(P)-ME is more
sensitive to ATP inhibition than WT m-NAD(P)-ME [18]. These
data suggest that Glu314 has opposite effects on ATP binding in
m-NAD(P)-ME and c-NADP-ME.
Nucleotide-binding site of malic enzyme
Crystal structures of the nucleotide-binding sites of pigeon c-
NADP-ME, human m-NAD(P)-ME and Ascaris suum m-NAD-ME
are illustrated in Figure 3 and may be used as models for the
human WT, S346K/K347Y/K362Q and E314A/S346I/
K347D/K362H c-NADP-ME variants, respectively, to explain
the molecular basis of the nucleotide-binding selectivity of malic
enzyme.
At the nucleotide-binding site of pigeon c-NADP-ME, Lys362
and Ser346 interact directly with the 29-phosphate of NADP
+
(Figure 3A). Lys362 is ion-paired with the 29-phosphate of NADP
+
and is involved in the electrostatic network of Asp345 and Arg354;
these interactions make the carboxylic side-chain of Asp345
deviate from the 29-phosphate of NADP
+, thereby reducing the
repulsion between Asp345 and NADP
+ and enhancing the affinity
for NADP
+ in the active site. Thus, the repulsive effect of Glu314
seems to be insignificant for NADP
+ binding by this isoform
because of its high affinity toward NADP
+. Ser346 in c-NADP-
ME is hydrogen-bonded to the 29-phosphate of NADP
+ and may
assist in the binding of NADP
+ (Figure 3A). Lys347 does not
directly interact with NADP
+. The positive charge of Lys347 may
play a role in maintaining electrostatic balance in the nucleotide-
binding site, thereby increasing the affinity for NADP
+.
Lys362 in c-NADP-ME plays a major role in governing NADP
+
specificity [30,31], while Gln362 in human m-NAD(P)-ME mainly
contributes to dual-cofactor specificity [14,31] and Lys346 and
Tyr347 are suggested to be collaborators that cooperatively confer
cofactor selectivity. Therefore, the nucleotide-binding site of
Table 4. Residues involved in ATP inhibition for human wild-type and nucleotide-binding mutant c-NADP-ME variants.
c-NADP-ME Residue
aATP inhibition (%)
314 346 347 362
bNAD
+ bNADP
+
WT E S K K 87.3 99.4
E314A A S K K 47.3 96.6
S346K E K K K 83.8 96.8
E314A/S346K A K K K 33.2 99.3
K347Y E S Y K 94.2 96.6
K362Q E S K Q 95.4 99.8
K362H E S K H 88.0 89.3
S346K/K347Y E K Y K 75.2 86.7
S346K/K362Q E K K Q 86.5 91.8
K347Y/K362Q E S Y Q 99.2 91.6
S346K/K347Y/K362Q E K Y Q 71.4 81.3
E314A/S346K/K347Y/K362Q A K Y Q 64.5 64.7
S346K/K347Y/K362H E K Y H 82.9 78.8
E314A/S346K/K347Y/K362H A K Y H 76.2 75.0
S346I/K347D/K362H E I D H 88.5 83.1
E314A/S346I/K347D/K362H A I D H 98.6 90.6
aResidual enzyme activity by inhibition at 3 mM ATP.
busing NAD
+ or NADP
+ as the cofactor.
doi:10.1371/journal.pone.0025312.t004
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human m-NAD(P)-ME (Figure 3B); the reverse effect for this
mutant enzyme on cofactor preference, switching from NADP
+ to
NAD
+, was observed. However, the E314A/S346K/K347Y/
K362Q c-NADP-ME showed greater favor for NAD
+ than
S346K/K347Y/K362Q c-NADP-ME. We have demonstrated
that the E314A m-NAD(P)-ME has a smaller Km,NAD value than
WT m-NAD(P)-ME [18]. Considering the much smaller Km of
NADP
+ for c-NADP-ME, the relatively higher Km of NAD
+ for m-
NAD(P)-ME may be caused by the negative charge of Glu314.
The E314A/S346I/K347D/K362H c-NADP-ME, mimicking
the Ascaris suum m-NAD-ME, was a NAD
+-preferring and ATP-
insensitive enzyme. The nucleotide-binding site of E314A/S346I/
K347D/K362H c-NADP-ME may be similar to that of Ascaris
suum m-NAD-ME (Figure 3C). Hydrophobic Ile346 and negative-
ly-charged Asp347 have a significant repulsive effect on NADP
+
and ATP. Previous work with Ascaris suum m-NAD-ME indicated
that mutation of His362 to Lys did not cause a shift in cofactor
specificity of the enzyme from NAD
+ to NADP
+ and that His362
in Ascaris suum m-NAD-ME is a second-layer residue in cofactor
interaction [32]. According to our results here, we propose that
replacement of Ile346 and Asp347 with Ser and Lys, respectively,
in Ascaris suum m-NAD-ME may have an effect on changing the
enzyme’s cofactor preference to NADP
+.
Considering these kinetic data collectively, we conclude that the
quadruple mutants containing the E314A mutation display NAD
+
specificity by significantly decreasing Km,NAD and Km,mal(NAD) and
increasing kcat,NAD. These results indicate that in addition to
residues 346, 347 and 362, Glu314 is also a determinant of
nucleotide-binding affinity in malic enzyme.
Materials and Methods
Expression, purification, and characterization of human
c-NADP-ME
The cDNA encoding c-NADP-ME was sub-cloned into the
pET21b vector, which carries a C-terminal His6?Tag sequence.
The Escherichia coli BL21(DE3) strain was transformed with the
expression vector, which includes an inducible T7 promoter
system. Enzyme overexpression was induced by 1.0 mM isopropyl
b-D-1-thiogalactopyranoside (IPTG), and the overexpressed
enzyme was purified using a HIS-Select
TM Nickel Affinity Gel
column (Sigma). The lysate-Ni-NTA mixture was washed with
buffer (10 mM imidazole, 500 mM sodium chloride, 2 mM b-
mercaptoethanol, and 30 mM Tris-HCl, pH 7.4) to remove
unwanted proteins, and the c-NADP-ME was subsequently eluted
with elution buffer (250 mM imidazole, 500 mM sodium chloride,
2m Mb-mercaptoethanol, and 30 mM Tris-HCl, pH 7.4).
The purified enzyme was buffer-exchanged and concentrated
with an Amicon Ultra-15 centrifugal filter (Millipore Corp.) and
preserved in 30 mM Tris-HCl (pH 7.4) with 2 mM b-mercapto-
ethanol. Enzyme purity was examined by SDS-PAGE, and protein
concentration was determined by the Bradford method [33].
Site-directed mutagenesis
Single (S346K, K347Y, and K362Q), double (S346K/K347Y,
S346K/K362Q, and K347Y/K362Q), and triple (S346K/K347Y/
K362Q) mutants were constructed by the QuikChange
TM kit
(Stratagene), using a plasmid containing the open reading frame
encoding human c-NADP-ME as template for the mutagenesis. The
PCR primers were as follows: 59-C C A A G G A G C T G G A GCG-
GCTGCCCTAGGG-39 for E314A; 59-GATATGGCTGGTTGA-
TAAAAAAGGATTAATAGTTAAGGG-39 for S346K; 59-GGC-
TGGTTGATTCATACGGATTAATAGTTAAGGGACG-39 for
K347Y; 59-GCTTCCTTAACACAAGAGCAGGAGAAGTTTG-
CCCATG-39 for K362Q; 59-GATATGGCTGGTTGATAAAT-
ACGGATTAATAGTTAAGGG-39 for S346K/K347Y; 59-GCT-
TCCTTAACACAAGAGCACGAGAAGTTTGCCCATG-39 for
K362H; and 59-GATATGGCTGGTTGATATCGACGGATTA-
ATAGTTAAGGGACG-39 for S346I/K347D. The PCR reaction
used Pfu DNA polymerase and was performed at 95uCf o r3 0s e c ,
55uC for 1 min, and 68uC for 2 min/kb of plasmid length for 16
cycles. The templates were digested with the DpnIr e s t r i c t i o ne n z y m e
and transformed into E. coli XL-1 cells. All mutation sites were
confirmed by automated sequencing.
Enzyme kinetic analysis
The malic enzyme reaction was assayed in a reaction buffer
including saturating concentrations of L-malate, NAD
+ or NADP
+
and MgCl2 in 50 mM Tris-HCl (pH 7.4) in a total volume of
1m La t3 0 uC. For Km,mal determination, the concentrations of
NAD(P)
+ and MgCl2 were fixed at 1 mM and 10 mM,
respectively, with various [malate]; for Km,Mg determination, the
concentrations of malate and NAD(P)
+ were fixed at 15 mM and
1 mM, respectively, with various [Mg
2+]; the malate and MgCl2
concentrations for Km,NAD or Km,NADP determination were fixed at
Figure 3. NAD
+ or NADP
+ cofactors in the nucleotide-binding pocket of the active center of malic enzyme. (A) The NADP-binding
pocket of the pigeon c-NADP-ME (PDB code 1GQ2). (B) The NAD-binding pocket of the human m-NAD(P)-ME (PDB code 1PJ3). (C) The NAD-binding
pocket of the Ascaris suum m-NAD-ME (PDB code 1LLQ). The gray dashed lines produced using PyMOL (DeLano Scientific LLC, San Carlos, CA)
represent the polar contacts between the amino acid residues and NAD
+ or NADP
+.
doi:10.1371/journal.pone.0025312.g003
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+]o r
[NADP
+]. The enzyme concentration used in these experiments
was 5 mg/mL. Absorbance at 340 nm was continuously monitored
in a UV/VIS Spectrophotometer Lambda 25 (Perkin Elmer,
USA). An absorption coefficient of 6.22 mM
21 at 340 nm for
NAD(P)H was used in the calculations. Apparent Michaelis
constants for the substrate or the cofactor were determined by
varying one substrate concentration near its Km value while
maintaining the other components constant at saturation levels.
All calculations were conducted using the Sigma Plot 10.0
program (Jandel, San Rafael, CA). The kcat value of c-NADP-
ME was calculated by the following equation:
kcat (s-1)~f½(v=6:22)= g protein  Molecular weightg=60
where v represents DA340/min, 6.22 is the millimolar absorption
coefficient of NAD(P)H, 260,000 is the molecular weight of a
tetramer of human c-NADP-ME and 60 is the number of seconds
in one minute.
The ATP inhibition experiment was assayed with 50 mM Tris-
HCl (pH 7.4), 40 mM malate (pH 7.4), 10 mM MgCl2, and
1.0 mM NAD
+ or NADP
+ (pH 7.4) at a series of ATP
concentrations, ranging from 0 to 3 mM. The Ki value of all
enzymes were assayed with the reaction buffer consisting of
50 mM Tris-HCl (pH 7.4), 20 mM malate (pH 7.4), and 10 mM
MgCl2 at a series of ATP concentrations around its Ki value and at
a series of NAD
+ or NADP
+ (pH 7.4) concentrations around its Km
value. The following equation was globally fitted to the total data
set, which describes a competitive inhibition pattern:
v~Vmax½S =f½S zKm(1z½ATP =Ki,ATP)g
where v is the observed initial velocity, Vmax is the maximum rate
of the reaction, Km is the Michaelis constant for the substrate, and
Ki,ATP is the inhibition constant for ATP.
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